Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1530 entries
Sorted by: Best Match Show Resources per page
Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report.

Journal of medical case reports

Iqbal M, Monaghan T, Redmond J.
PMID: 22313512
J Med Case Rep. 2012 Feb 07;6:52. doi: 10.1186/1752-1947-6-52.

INTRODUCTION: Neurologic consequences of manganese toxicity have been recognized since 1837. A new form of presumed manganese poisoning has been reported in drug-addicted persons from Eastern Europe and the Baltic states who have intravenously injected self-prepared methcathinone hydrochloride (ephedrone),...

Cite
Iqbal M, Monaghan T, Redmond J. Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report. J Med Case Rep. 2012;6:52doi: 10.1186/1752-1947-6-52.
Iqbal, M., Monaghan, T., & Redmond, J. (2012). Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report. Journal of medical case reports, 652. https://doi.org/10.1186/1752-1947-6-52
Iqbal, Mudassir, et al. "Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report." Journal of medical case reports vol. 6 (2012): 52. doi: https://doi.org/10.1186/1752-1947-6-52
Iqbal M, Monaghan T, Redmond J. Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report. J Med Case Rep. 2012 Feb 07;6:52. doi: 10.1186/1752-1947-6-52. PMID: 22313512; PMCID: PMC3292443.
Copy Download .nbib Format: NLM
Serial macro-architectural alterations with levodopa in Parkinson's disease: Polysomnography (PSG)-based analysis.

Annals of Indian Academy of Neurology

Joy SP, Sinha S, Pal PK, Panda S, Philip M, Taly AB.
PMID: 26425009
Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):309-13. doi: 10.4103/0972-2327.160102.

PURPOSE: We studied the sleep macroarchitecture with polysomnography (PSG) in drug naïve patients with Parkinson's disease (PD) and reassessed them following treatment with levodopa.MATERIALS AND METHODS: This prospective hospital-based study included 15 patients with PD (age: 59 ± 11.2...

Cite
Joy SP, Sinha S, Pal PK, et al. Serial macro-architectural alterations with levodopa in Parkinson's disease: Polysomnography (PSG)-based analysis. Ann Indian Acad Neurol. 2015;18(3):309-13doi: 10.4103/0972-2327.160102.
Joy, S. P., Sinha, S., Pal, P. K., Panda, S., Philip, M., & Taly, A. B. (2015). Serial macro-architectural alterations with levodopa in Parkinson's disease: Polysomnography (PSG)-based analysis. Annals of Indian Academy of Neurology, 18(3), 309-13. https://doi.org/10.4103/0972-2327.160102
Joy, Sanju P, et al. "Serial macro-architectural alterations with levodopa in Parkinson's disease: Polysomnography (PSG)-based analysis." Annals of Indian Academy of Neurology vol. 18,3 (2015): 309-13. doi: https://doi.org/10.4103/0972-2327.160102
Joy SP, Sinha S, Pal PK, Panda S, Philip M, Taly AB. Serial macro-architectural alterations with levodopa in Parkinson's disease: Polysomnography (PSG)-based analysis. Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):309-13. doi: 10.4103/0972-2327.160102. PMID: 26425009; PMCID: PMC4564466.
Copy Download .nbib Format: NLM
Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson's Disease: Therapeutic and Adverse Effects.

Journal of movement disorders

Ryu HS, Kim MS, You S, Kim MJ, Kim YJ, Kim J, Kim K, Chung SJ.
PMID: 28479586
J Mov Disord. 2017 May;10(2):80-86. doi: 10.14802/jmd.17001. Epub 2017 May 08.

OBJECTIVE: To compare the therapeutic and adverse effects of globus pallidus interna (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of advanced Parkinson's disease (PD).METHODS: We retrospectively analyzed the clinical data of patients with PD...

Cite
Ryu HS, Kim MS, You S, et al. Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson's Disease: Therapeutic and Adverse Effects. J Mov Disord. 2017;10(2):80-86doi: 10.14802/jmd.17001.
Ryu, H. S., Kim, M. S., You, S., Kim, M. J., Kim, Y. J., Kim, J., Kim, K., & Chung, S. J. (2017). Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson's Disease: Therapeutic and Adverse Effects. Journal of movement disorders, 10(2), 80-86. https://doi.org/10.14802/jmd.17001
Ryu, Ho-Sung, et al. "Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson's Disease: Therapeutic and Adverse Effects." Journal of movement disorders vol. 10,2 (2017): 80-86. doi: https://doi.org/10.14802/jmd.17001
Ryu HS, Kim MS, You S, Kim MJ, Kim YJ, Kim J, Kim K, Chung SJ. Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson's Disease: Therapeutic and Adverse Effects. J Mov Disord. 2017 May;10(2):80-86. doi: 10.14802/jmd.17001. Epub 2017 May 08. PMID: 28479586; PMCID: PMC5435836.
Copy Download .nbib Format: NLM
Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease.

Clinical and translational gastroenterology

Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER, Robieson WZ, Eaton S, Dubow J, Chatamra K, Benesh J.
PMID: 27030949
Clin Transl Gastroenterol. 2016 Mar 31;7:e159. doi: 10.1038/ctg.2016.19.

OBJECTIVES: The objectives of this study were to present procedure- and device-associated adverse events (AEs) identified with long-term drug delivery via percutaneous endoscopic gastrojejunostomy (PEG-J). Levodopa-carbidopa intestinal gel (LCIG, also known in US as carbidopa-levodopa enteral suspension, CLES) is...

Cite
Epstein M, Johnson DA, Hawes R, et al. Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clin Transl Gastroenterol. 2016;7:e159doi: 10.1038/ctg.2016.19.
Epstein, M., Johnson, D. A., Hawes, R., Schmulewitz, N., Vanagunas, A. D., Gossen, E. R., Robieson, W. Z., Eaton, S., Dubow, J., Chatamra, K., & Benesh, J. (2016). Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clinical and translational gastroenterology, 7e159. https://doi.org/10.1038/ctg.2016.19
Epstein, Michael, et al. "Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease." Clinical and translational gastroenterology vol. 7 (2016): e159. doi: https://doi.org/10.1038/ctg.2016.19
Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER, Robieson WZ, Eaton S, Dubow J, Chatamra K, Benesh J. Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clin Transl Gastroenterol. 2016 Mar 31;7:e159. doi: 10.1038/ctg.2016.19. PMID: 27030949; PMCID: PMC4822096.
Copy Download .nbib Format: NLM
Evolution of visual art with dopaminergic therapy.

Journal of clinical movement disorders

Walker RH.
PMID: 27004128
J Clin Mov Disord. 2016 Mar 21;3:6. doi: 10.1186/s40734-016-0034-y. eCollection 2016.

A patient with right-side-predominant Parkinson's disease presented visual artwork which improved in resemblance to the model which he was copying with increasing doses of levodopa. I propose that increased dopaminergic replacement resulted in improved attention to detail, mediated by...

Cite
Walker RH. Evolution of visual art with dopaminergic therapy. J Clin Mov Disord. 2016;3:6doi: 10.1186/s40734-016-0034-y.
Walker, R. H. (2016). Evolution of visual art with dopaminergic therapy. Journal of clinical movement disorders, 36. https://doi.org/10.1186/s40734-016-0034-y
Walker, Ruth H. "Evolution of visual art with dopaminergic therapy." Journal of clinical movement disorders vol. 3 (2016): 6. doi: https://doi.org/10.1186/s40734-016-0034-y
Walker RH. Evolution of visual art with dopaminergic therapy. J Clin Mov Disord. 2016 Mar 21;3:6. doi: 10.1186/s40734-016-0034-y. eCollection 2016. PMID: 27004128; PMCID: PMC4800775.
Copy Download .nbib Format: NLM
Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes.

Beilstein journal of nanotechnology

Tan JM, Foo JB, Fakurazi S, Hussein MZ.
PMID: 25671168
Beilstein J Nanotechnol. 2015 Jan 22;6:243-53. doi: 10.3762/bjnano.6.23. eCollection 2015.

This work explores the potential use of commercially obtained, carboxylated, single-walled carbon nanotubes (SWCNT-COOH) as nanocarriers for the antiparkinson drug, levodopa (LD). The resulting nanohybrid was characterized using materials characterization methods including Fourier transform infrared spectroscopy, Raman spectroscopy, elemental...

Cite
Tan JM, Foo JB, Fakurazi S, et al. Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol. 2015;6:243-53doi: 10.3762/bjnano.6.23.
Tan, J. M., Foo, J. B., Fakurazi, S., & Hussein, M. Z. (2015). Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein journal of nanotechnology, 6243-53. https://doi.org/10.3762/bjnano.6.23
Tan, Julia M, et al. "Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes." Beilstein journal of nanotechnology vol. 6 (2015): 243-53. doi: https://doi.org/10.3762/bjnano.6.23
Tan JM, Foo JB, Fakurazi S, Hussein MZ. Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol. 2015 Jan 22;6:243-53. doi: 10.3762/bjnano.6.23. eCollection 2015. PMID: 25671168; PMCID: PMC4311623.
Copy Download .nbib Format: NLM
Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism.

Journal of clinical and diagnostic research : JCDR

Merajoth AL, Pillai PS, Iype T.
PMID: 27437241
J Clin Diagn Res. 2016 May;10(5):FC07-10. doi: 10.7860/JCDR/2016/16043.7886. Epub 2016 May 01.

INTRODUCTION: Parkinson's disease is the most common form of a group of progressive neurodegenerative disorders. The use of levodopa as dopamine - replacement therapy is highly effective in ameliorating the symptoms of the disease and remains the standard drug...

Cite
Merajoth AL, Pillai PS, Iype T. Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism. J Clin Diagn Res. 2016;10(5):FC07-10doi: 10.7860/JCDR/2016/16043.7886.
Merajoth, A. L., Pillai, P. S., & Iype, T. (2016). Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism. Journal of clinical and diagnostic research : JCDR, 10(5), FC07-10. https://doi.org/10.7860/JCDR/2016/16043.7886
Merajoth, Abhijith Lalesh, et al. "Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism." Journal of clinical and diagnostic research : JCDR vol. 10,5 (2016): FC07-10. doi: https://doi.org/10.7860/JCDR/2016/16043.7886
Merajoth AL, Pillai PS, Iype T. Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism. J Clin Diagn Res. 2016 May;10(5):FC07-10. doi: 10.7860/JCDR/2016/16043.7886. Epub 2016 May 01. PMID: 27437241; PMCID: PMC4948417.
Copy Download .nbib Format: NLM
Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Therapeutic advances in neurological disorders

Virhammar J, Nyholm D.
PMID: 28344656
Ther Adv Neurol Disord. 2017 Mar;10(3):171-187. doi: 10.1177/1756285616681280. Epub 2016 Dec 01.

The duration of action of oral levodopa becomes shorter as Parkinson's disease (PD) progresses. Patients with advanced PD may develop potentially disabling motor fluctuations and abnormal involuntary movement (dyskinesia), which cannot be managed with optimized oral or transdermal PD...

Cite
Virhammar J, Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. Ther Adv Neurol Disord. 2016;10(3):171-187doi: 10.1177/1756285616681280.
Virhammar, J., & Nyholm, D. (2017). Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. Therapeutic advances in neurological disorders, 10(3), 171-187. https://doi.org/10.1177/1756285616681280
Virhammar, Johan, and Nyholm, Dag. "Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience." Therapeutic advances in neurological disorders vol. 10,3 (2017): 171-187. doi: https://doi.org/10.1177/1756285616681280
Virhammar J, Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. Ther Adv Neurol Disord. 2017 Mar;10(3):171-187. doi: 10.1177/1756285616681280. Epub 2016 Dec 01. PMID: 28344656; PMCID: PMC5349373.
Copy Download .nbib Format: NLM
Clinical characteristics of epileptic seizures in a case of dihydropteridine reductase deficiency.

Epilepsy & behavior case reports

Furujo M, Kinoshita M, Ichiba Y, Romstad A, Shintaku H, Kubo T.
PMID: 25667865
Epilepsy Behav Case Rep. 2014 Mar 13;2:37-9. doi: 10.1016/j.ebcr.2014.01.007. eCollection 2014.

We assessed the clinical characteristics and efficacy of neurotransmitters and levetiracetam in a patient with hyperphenylalaninemia due to dihydropteridine reductase (DHPR) deficiency who developed epileptic seizures. A boy with DHPR deficiency, who had been successfully treated with tetrahydrobiopterin (BH4),...

Cite
Furujo M, Kinoshita M, Ichiba Y, et al. Clinical characteristics of epileptic seizures in a case of dihydropteridine reductase deficiency. Epilepsy Behav Case Rep. 2014;2:37-9doi: 10.1016/j.ebcr.2014.01.007.
Furujo, M., Kinoshita, M., Ichiba, Y., Romstad, A., Shintaku, H., & Kubo, T. (2014). Clinical characteristics of epileptic seizures in a case of dihydropteridine reductase deficiency. Epilepsy & behavior case reports, 237-9. https://doi.org/10.1016/j.ebcr.2014.01.007
Furujo, Mahoko, et al. "Clinical characteristics of epileptic seizures in a case of dihydropteridine reductase deficiency." Epilepsy & behavior case reports vol. 2 (2014): 37-9. doi: https://doi.org/10.1016/j.ebcr.2014.01.007
Furujo M, Kinoshita M, Ichiba Y, Romstad A, Shintaku H, Kubo T. Clinical characteristics of epileptic seizures in a case of dihydropteridine reductase deficiency. Epilepsy Behav Case Rep. 2014 Mar 13;2:37-9. doi: 10.1016/j.ebcr.2014.01.007. eCollection 2014. PMID: 25667865; PMCID: PMC4308063.
Copy Download .nbib Format: NLM
Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias.

Case reports in neurology

Sherman SJ, Estevez M, Magill AB, Falk T.
PMID: 27293405
Case Rep Neurol. 2016 Feb 26;8(1):53-8. doi: 10.1159/000444278. eCollection 2016.

Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in...

Cite
Sherman SJ, Estevez M, Magill AB, et al. Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias. Case Rep Neurol. 2016;8(1):53-8doi: 10.1159/000444278.
Sherman, S. J., Estevez, M., Magill, A. B., & Falk, T. (2016). Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias. Case reports in neurology, 8(1), 53-8. https://doi.org/10.1159/000444278
Sherman, Scott J, et al. "Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias." Case reports in neurology vol. 8,1 (2016): 53-8. doi: https://doi.org/10.1159/000444278
Sherman SJ, Estevez M, Magill AB, Falk T. Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias. Case Rep Neurol. 2016 Feb 26;8(1):53-8. doi: 10.1159/000444278. eCollection 2016. PMID: 27293405; PMCID: PMC4899651.
Copy Download .nbib Format: NLM
Automatic behavior and communication due to pramipexole.

Journal of clinical movement disorders

Walker RH.
PMID: 27403333
J Clin Mov Disord. 2016 Jul 11;3:9. doi: 10.1186/s40734-016-0038-7. eCollection 2016.

A 45-year-old woman reported automatic behaviors and communication whilst she was being treated with pramipexole. These episodes vanished after the medication was tapered and she was started on levodopa/carbidopa. I hypothesize that the episodes were related to disordered awareness...

Cite
Walker RH. Automatic behavior and communication due to pramipexole. J Clin Mov Disord. 2016;3:9doi: 10.1186/s40734-016-0038-7.
Walker, R. H. (2016). Automatic behavior and communication due to pramipexole. Journal of clinical movement disorders, 39. https://doi.org/10.1186/s40734-016-0038-7
Walker, Ruth H. "Automatic behavior and communication due to pramipexole." Journal of clinical movement disorders vol. 3 (2016): 9. doi: https://doi.org/10.1186/s40734-016-0038-7
Walker RH. Automatic behavior and communication due to pramipexole. J Clin Mov Disord. 2016 Jul 11;3:9. doi: 10.1186/s40734-016-0038-7. eCollection 2016. PMID: 27403333; PMCID: PMC4939520.
Copy Download .nbib Format: NLM
The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease.

Sleep science (Sao Paulo, Brazil)

Távora DG, de Bruin VM, Lopes Gama R, Lopes EM, Jorge IF, de Bruin PF.
PMID: 26483896
Sleep Sci. 2014 Mar;7(1):13-8. doi: 10.1016/j.slsci.2014.07.020. Epub 2014 Aug 22.

OBJECTIVES: Excessive daytime sleepiness (EDS) and sudden sleep onset (SOS) episodes are frequent in Parkinson׳s disease (PD). The objectives are to identify clinical characteristics and factors associated with EDS and SOS episodes.METHODS: Clinical demographic data were recorded (N=100, mean...

Cite
Távora DG, de Bruin VM, Lopes Gama R, et al. The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease. Sleep Sci. 2014;7(1):13-8doi: 10.1016/j.slsci.2014.07.020.
Távora, D. G., de Bruin, V. M., Lopes Gama, R., Lopes, E. M., Jorge, I. F., & de Bruin, P. F. (2014). The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease. Sleep science (Sao Paulo, Brazil), 7(1), 13-8. https://doi.org/10.1016/j.slsci.2014.07.020
Távora, Daniel Gurgel Fernandes, et al. "The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease." Sleep science (Sao Paulo, Brazil) vol. 7,1 (2014): 13-8. doi: https://doi.org/10.1016/j.slsci.2014.07.020
Távora DG, de Bruin VM, Lopes Gama R, Lopes EM, Jorge IF, de Bruin PF. The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease. Sleep Sci. 2014 Mar;7(1):13-8. doi: 10.1016/j.slsci.2014.07.020. Epub 2014 Aug 22. PMID: 26483896; PMCID: PMC4521648.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1530 entries